First patient dosed in the Phase 1, first-in-human study of LAVA-1266, marking a significant milestone for the company. LAVA-1266 has demonstrated a strong preclinical safety and efficacy profile, ...
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback